Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOVON phase III trial of bortezomib-based induction and maintenance in multiple myeloma
ISRCTN64455289Phase 3Completed
- Sponsor
- HOVON
- Start
- May 2005
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of bortezomib, doxorubicin, dexamethasone, vincristine, melphalan and 1 more in multiple myeloma (MM) (2 arms), sponsored by HOVON. Primary endpoint: Progression-free survival. Started May 2005; status: completed.
02
Drugs
bortezomibdoxorubicindexamethasonevincristinemelphalan
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ISRCTN64455289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN64455289.